Elafibranor (GFT505) a experimental medication that is being studied and developed by Genfit for the treatment of cardiometabolic diseases including diabetes, insulin resistance, dyslipidemia, and non-alcoholic fatty liver disease (NAFLD).
Elafibranor is a dual PPARα/δ agonist.
Elifibranor is mainly focused on the treatment of NASH disease.
Administered to over 800 patients and healthy volunteers to date, Elafibranor has demonstrated :
As of February 2016 GFT505 has completed 8 clinical trials and none are in progress.
Efficacy on histological NASH parameters (steatosis, inflammation, fibrosis) in animal disease models – anti-fibrotic activities
The absence of safety concern has been confirmed in a full toxicological package up to 2-year carcinogenicity studies and cardiac studies (in mice).
I've got passion and a reason,
And I won't neglect my emotions,
Because I wanna spill, spill my guts,
But I don't want to pick them up,
I've got passion, and a reason,
And I won't neglect my emotions,
I'm excited and I'm exploding,
I'm ignited and I'm ready to go off
Rather be caught dead than weak
Cause I'd rather be caught dead, than be weak,
And in my last days I'll still be standing strong,
Cause I'd rather be caught dead, than be weak,
And in my last days I'll still be standing strong,
I wanna spill, spill my guts,
But I don't want to pick them up,
I've got too much pride and desire,
To let this go, I'll walk through fire
I've got passion, and a reason,
And I won't neglect my emotions
Rather be caught dead than weak
I'd rather be caught dead than weak,